JP2000513333A - ポリマーを基剤とした制御された放出デバイスの製造方法 - Google Patents
ポリマーを基剤とした制御された放出デバイスの製造方法Info
- Publication number
- JP2000513333A JP2000513333A JP09540906A JP54090697A JP2000513333A JP 2000513333 A JP2000513333 A JP 2000513333A JP 09540906 A JP09540906 A JP 09540906A JP 54090697 A JP54090697 A JP 54090697A JP 2000513333 A JP2000513333 A JP 2000513333A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- polymer
- solvent
- polymer solution
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 300
- 238000004519 manufacturing process Methods 0.000 title description 8
- 238000013270 controlled release Methods 0.000 title description 3
- 229940079593 drug Drugs 0.000 claims abstract description 336
- 239000003814 drug Substances 0.000 claims abstract description 336
- 239000011159 matrix material Substances 0.000 claims abstract description 167
- 238000000034 method Methods 0.000 claims abstract description 123
- 239000000203 mixture Substances 0.000 claims abstract description 116
- 239000002904 solvent Substances 0.000 claims abstract description 88
- 239000011859 microparticle Substances 0.000 claims abstract description 49
- 239000007787 solid Substances 0.000 claims abstract description 39
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 238000007710 freezing Methods 0.000 claims abstract description 24
- 230000008014 freezing Effects 0.000 claims abstract description 23
- 239000003960 organic solvent Substances 0.000 claims abstract description 20
- 230000009477 glass transition Effects 0.000 claims abstract description 10
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 9
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 9
- 239000002157 polynucleotide Substances 0.000 claims abstract description 9
- 102000003951 Erythropoietin Human genes 0.000 claims description 50
- 108090000394 Erythropoietin Proteins 0.000 claims description 50
- 229940105423 erythropoietin Drugs 0.000 claims description 50
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 50
- 239000002245 particle Substances 0.000 claims description 48
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 239000003607 modifier Substances 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 238000005507 spraying Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000000227 grinding Methods 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000007789 gas Substances 0.000 claims description 9
- -1 antibodies Proteins 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940088679 drug related substance Drugs 0.000 claims description 6
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 239000010419 fine particle Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 4
- 229920001710 Polyorthoester Polymers 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 238000003801 milling Methods 0.000 claims description 4
- 229920002635 polyurethane Polymers 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 3
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 239000004570 mortar (masonry) Substances 0.000 claims description 3
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920002959 polymer blend Polymers 0.000 claims description 3
- 229920006324 polyoxymethylene Polymers 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000011877 solvent mixture Substances 0.000 claims 4
- 238000001704 evaporation Methods 0.000 claims 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 2
- 229930182556 Polyacetal Natural products 0.000 claims 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 2
- 229920013641 bioerodible polymer Polymers 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 239000002745 poly(ortho ester) Substances 0.000 claims 2
- 230000001376 precipitating effect Effects 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 101100181034 Drosophila melanogaster Khc gene Proteins 0.000 claims 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 claims 1
- 229910052786 argon Inorganic materials 0.000 claims 1
- 238000010030 laminating Methods 0.000 claims 1
- 229920003168 pharmaceutical polymer Polymers 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229920000249 biocompatible polymer Polymers 0.000 abstract description 12
- 239000000243 solution Substances 0.000 description 62
- 238000001727 in vivo Methods 0.000 description 10
- 235000012431 wafers Nutrition 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000004005 microsphere Substances 0.000 description 8
- 239000007943 implant Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 3
- 229960003086 naltrexone Drugs 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001192 hot extrusion Methods 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241001427367 Gardena Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-M chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000010128 melt processing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940063122 sandimmune Drugs 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Polymerisation Methods In General (AREA)
- Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/649,128 US5817343A (en) | 1996-05-14 | 1996-05-14 | Method for fabricating polymer-based controlled-release devices |
| US08/649,128 | 1996-05-14 | ||
| PCT/US1997/007441 WO1997042940A1 (en) | 1996-05-14 | 1997-05-01 | Method for fabricating polymer-based controlled-release devices |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000513333A true JP2000513333A (ja) | 2000-10-10 |
| JP2000513333A5 JP2000513333A5 (enExample) | 2005-01-13 |
Family
ID=24603582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09540906A Ceased JP2000513333A (ja) | 1996-05-14 | 1997-05-01 | ポリマーを基剤とした制御された放出デバイスの製造方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US5817343A (enExample) |
| EP (1) | EP0914095B1 (enExample) |
| JP (1) | JP2000513333A (enExample) |
| AT (1) | ATE221373T1 (enExample) |
| AU (1) | AU718866B2 (enExample) |
| CA (1) | CA2253667A1 (enExample) |
| DE (1) | DE69714448T2 (enExample) |
| DK (1) | DK0914095T3 (enExample) |
| ES (1) | ES2180982T3 (enExample) |
| PT (1) | PT914095E (enExample) |
| WO (1) | WO1997042940A1 (enExample) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009545564A (ja) * | 2006-08-02 | 2009-12-24 | メディオラヌム ファルマチェウティカルズ リミテッド | 長時間にわたって活性本体を放出する皮下移植物 |
| JP2017500297A (ja) * | 2013-11-26 | 2017-01-05 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
| US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
| US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
Families Citing this family (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6013258A (en) * | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| US6183746B1 (en) | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| AU5532699A (en) * | 1998-09-05 | 2000-03-27 | Seung Jin Lee | Biodegradable particulate polymeric preparation and process for producing thereof |
| KR20000022894A (ko) * | 1998-09-05 | 2000-04-25 | 이승진 | 생분해성 고분자 미립자형 제제 및 그 제조방법 |
| DE19848849A1 (de) * | 1998-10-22 | 2000-04-27 | Knoll Ag | Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz |
| JP2002534371A (ja) * | 1999-01-06 | 2002-10-15 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物 |
| US6159491A (en) * | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
| KR100372751B1 (ko) * | 1999-11-16 | 2003-02-17 | 한국과학기술원 | 생체조직공학용 다공성 생분해성 고분자 지지체의 제조방법 |
| US6440463B1 (en) * | 1999-04-05 | 2002-08-27 | Pharmaceutical Discovery Corporation | Methods for fine powder formation |
| WO2000062759A1 (en) * | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Dry, mouldable drug formulation |
| US7759113B2 (en) * | 1999-04-30 | 2010-07-20 | The General Hospital Corporation | Fabrication of tissue lamina using microfabricated two-dimensional molds |
| US7371400B2 (en) | 2001-01-02 | 2008-05-13 | The General Hospital Corporation | Multilayer device for tissue engineering |
| WO2000066036A2 (en) * | 1999-04-30 | 2000-11-09 | Massachusetts General Hospital | Fabrication of vascularized tissue using microfabricated two-dimensional molds |
| US6291013B1 (en) | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
| US6444223B1 (en) | 1999-05-28 | 2002-09-03 | Alkermes Controlled Therapeutics, Inc. | Method of producing submicron particles of a labile agent and use thereof |
| IL146814A0 (en) * | 1999-06-04 | 2002-07-25 | Alza Corp | Implantable gel compositions and method of manufacture |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| EP1074248A1 (en) * | 1999-07-08 | 2001-02-07 | Arnold Hilgers | Delivery system for biological material |
| US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| US6822086B1 (en) * | 1999-08-09 | 2004-11-23 | The General Hospital Corporation | Drug-carrier complexes and methods of use thereof |
| AU6536400A (en) * | 1999-08-11 | 2001-03-05 | Alkermes Controlled Therapeutics, Inc. | Method of delivering a chemotherapeutic agent to a solid tumor |
| US6284283B1 (en) | 1999-10-21 | 2001-09-04 | Alkermes Controlled Therapeutics, Inc. | Method of producing sub-micron particles of biologically active agents and uses thereof |
| WO2001030320A1 (en) * | 1999-10-22 | 2001-05-03 | Amgen Inc. | Biodegradable microparticles with novel erythropoietin stimulating protein |
| AU2599501A (en) * | 1999-12-29 | 2001-07-09 | Advanced Cardiovascular Systems Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
| US7029700B2 (en) * | 2000-01-14 | 2006-04-18 | Brown University Research Foundation | Micronized freeze-dried particles |
| WO2001052818A1 (en) * | 2000-01-19 | 2001-07-26 | Pharmaceutical Discovery Corporation | Dry powder formulations of antihistamine for nasal administration |
| AU5289001A (en) * | 2000-03-02 | 2001-09-12 | Microchips Inc | Microfabricated devices for the storage and selective exposure of chemicals and devices |
| US7074803B2 (en) * | 2001-03-02 | 2006-07-11 | Durect Corporation | Opioid formulations |
| CA2402790A1 (en) | 2000-04-06 | 2001-10-18 | University Technology Corporation | Compositions and methods for promoting wound healing |
| US7776021B2 (en) | 2000-04-28 | 2010-08-17 | The Charles Stark Draper Laboratory | Micromachined bilayer unit for filtration of small molecules |
| DE60127139T2 (de) * | 2000-07-14 | 2007-12-13 | Novo Nordisk A/S | Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial |
| US6362308B1 (en) | 2000-08-10 | 2002-03-26 | Alkermes Controlled Therapeutics Inc. Ii | Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content |
| CA2419115C (en) | 2000-08-15 | 2011-03-08 | Board Of Trustees Of The University Of Illinois | Microparticles, and method and apparatus for forming same |
| US6565888B1 (en) | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
| ATE506942T1 (de) * | 2000-09-01 | 2011-05-15 | Palmaya Pty Ltd | Pharmazeutische zubereitung und methode diese zu verabreichen |
| US7666445B2 (en) | 2000-10-20 | 2010-02-23 | The Trustees Of The University Of Pennsylvania | Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use |
| AU3941002A (en) | 2000-10-31 | 2002-06-03 | Zycos Inc | Cyp1b1 nucleic acids and methods of use |
| WO2002062352A2 (en) * | 2001-02-07 | 2002-08-15 | Durect Corporation | Devices and methods for management of bone density |
| BR0209914A (pt) * | 2001-05-23 | 2004-04-06 | Hexal Ag | Produto homogeneizado para implantes e micropartìculas |
| US6730772B2 (en) | 2001-06-22 | 2004-05-04 | Venkatram P. Shastri | Degradable polymers from derivatized ring-opened epoxides |
| WO2003014224A1 (en) * | 2001-08-03 | 2003-02-20 | Toray Industries, Inc. | Resin composition and molded article, film, and fiber each comprising the same |
| US7687053B2 (en) | 2001-08-20 | 2010-03-30 | Boston Scientific Scimed, Inc. | Embolic compositions with non-cyanoacrylate rheology modifying agents |
| US8454997B2 (en) | 2001-12-18 | 2013-06-04 | Novo Nordisk A/S | Solid dose micro implant |
| US7190781B2 (en) * | 2002-01-04 | 2007-03-13 | Telefonaktiebolaget Lm Ericsson (Publ) | Message transfer part point code mapping method and node |
| AU2003209227A1 (en) * | 2002-01-14 | 2003-07-30 | The General Hospital Corporation | Biodegradable polyketal polymers and methods for their formation and use |
| CA2476452A1 (en) * | 2002-02-15 | 2003-08-28 | Zycos Inc. | Electroporation methods for introducing bioactive agents into cells |
| US8728510B1 (en) | 2002-03-15 | 2014-05-20 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing a bioadhesive material |
| AU2003220125B2 (en) | 2002-03-20 | 2006-06-15 | Mannkind Corporation | Inhalation apparatus |
| EP1534269B1 (en) | 2002-07-19 | 2013-10-30 | The General Hospital Corporation | Oxime conjugates and methods for their formation and use |
| GB2399084B (en) * | 2002-07-30 | 2007-01-31 | Univ Liverpool | Porous beads and method of production thereof |
| GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
| CN1694689A (zh) * | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| US6800663B2 (en) * | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| ATE439039T1 (de) | 2003-01-16 | 2009-08-15 | Gen Hospital Corp | Verwendung von dreidimensionalen, mikrogefertigten, mittels gewebetechnologie hergestellten systemen für pharmakologische anwendungen |
| WO2004064752A2 (en) * | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| DE10303584A1 (de) * | 2003-01-30 | 2004-08-12 | Stauss, Robert, Dr. | Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten |
| US7736391B2 (en) | 2003-02-06 | 2010-06-15 | Tonaba Healthscience Ii, Llc | Cosmetic and reconstructive prostheses with a microencapsulated biologically compatible rupture indicator for sustained release and methods of detecting compromise of a prosthesis |
| US20070122487A1 (en) * | 2003-03-19 | 2007-05-31 | University Of Kentucky Research Foundation | (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres |
| US7051485B2 (en) * | 2003-04-29 | 2006-05-30 | Greg Burnette | Ceiling panel system |
| US7960166B2 (en) | 2003-05-21 | 2011-06-14 | The General Hospital Corporation | Microfabricated compositions and processes for engineering tissues containing multiple cell types |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| US7790150B2 (en) * | 2003-09-05 | 2010-09-07 | The General Hospital Corporation | Dual phase drug release system |
| CN1856296A (zh) * | 2003-09-30 | 2006-11-01 | 阿库斯菲尔公司 | 可注射的、口服、或局部用缓释药物制剂 |
| JP2007507527A (ja) * | 2003-09-30 | 2007-03-29 | スフェリックス， インコーポレイテッド | 生物学的に活性なナノ粒子治療用因子 |
| US7309500B2 (en) * | 2003-12-04 | 2007-12-18 | The Board Of Trustees Of The University Of Illinois | Microparticles |
| ES2346226T3 (es) * | 2003-12-30 | 2010-10-13 | Augustinus Bader | Uso de la eritropoyetina para la regeneracion de tejido hepatico. |
| AU2005206143B2 (en) * | 2004-01-12 | 2010-12-16 | The Trustees Of The University Of Pennsylvania | Long-term delivery formulations and methods of use thereof |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| US8329203B2 (en) * | 2004-01-12 | 2012-12-11 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| US20050220887A1 (en) * | 2004-01-20 | 2005-10-06 | Alkermes Controlled Therapeutics, Inc. | Method for milling frozen microparticles |
| US20050188921A1 (en) * | 2004-02-27 | 2005-09-01 | Anthony Malone | Matrix assisted pulsed-laser evaporation technique for coating a medical device and associated system and medical device |
| DK1732921T3 (da) * | 2004-04-08 | 2009-02-23 | Wyeth Corp | Thiomidderivater som progesteronreceptormodulatorer |
| JP5039541B2 (ja) * | 2004-04-27 | 2012-10-03 | ワイス・エルエルシー | プロゲステロン受容体調節剤の精製 |
| WO2005110369A2 (en) * | 2004-04-30 | 2005-11-24 | American Pharmaceutical Partners, Inc. | Sustained-release microspheres and methods of making and using same |
| US8062652B2 (en) * | 2004-06-17 | 2011-11-22 | Endo Pharmaceuticals Solutions Inc. | Compositions and methods for treating precocious puberty |
| EP2594259A1 (en) | 2004-08-04 | 2013-05-22 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
| GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
| KR101273120B1 (ko) | 2004-08-20 | 2013-06-13 | 맨카인드 코포레이션 | 다이케토피페라진 합성의 촉매 작용 |
| KR20130066695A (ko) | 2004-08-23 | 2013-06-20 | 맨카인드 코포레이션 | 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염 |
| US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| WO2006036967A1 (en) * | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
| US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
| US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| WO2007011385A2 (en) | 2004-09-28 | 2007-01-25 | Atrium Medical Corporation | Heat cured gel and method of making |
| US8124127B2 (en) | 2005-10-15 | 2012-02-28 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
| US8834901B2 (en) * | 2004-10-14 | 2014-09-16 | Trustees Of Tufts College | Electrochemically degradable polymers |
| US7748343B2 (en) | 2004-11-22 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Electrohydrodynamic spraying system |
| US20080213593A1 (en) * | 2005-01-21 | 2008-09-04 | President And Fellows Of Harvard College | Systems And Methods For Forming Fluidic Droplets Encapsulated In Particles Such As Colloidal Particles |
| NZ561400A (en) * | 2005-03-11 | 2010-02-26 | Endo Pharmaceuticals Solutions | Controlled release formulations of octreotide |
| US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
| CN102614131A (zh) | 2005-09-14 | 2012-08-01 | 曼金德公司 | 以提高结晶微粒表面对活性试剂的亲和力为基础的药物配制方法 |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9427423B2 (en) * | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| US7669732B2 (en) * | 2005-10-25 | 2010-03-02 | Imi Cornelius Inc. | Cup lid dispenser |
| WO2007098500A2 (en) | 2006-02-22 | 2007-08-30 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| US8231907B2 (en) * | 2006-03-21 | 2012-07-31 | Morehouse School Of Medicine | Nanoparticles for delivery of active agents |
| CA2649915A1 (en) * | 2006-04-20 | 2007-11-01 | University Of Utah Research Foundation | Polymeric compositions and methods of making and using thereof |
| US8747870B2 (en) | 2006-04-20 | 2014-06-10 | University Of Utah Research Foundation | Polymeric compositions and methods of making and using thereof |
| GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
| GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
| US20080075777A1 (en) * | 2006-07-31 | 2008-03-27 | Kennedy Michael T | Apparatus and methods for preparing solid particles |
| ITMI20061538A1 (it) * | 2006-08-02 | 2008-02-03 | Mediolanum Pharmaceuticals Ltd | Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo |
| GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
| WO2008057344A2 (en) | 2006-11-06 | 2008-05-15 | Atrium Medical Corporation | Coated surgical mesh |
| US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
| WO2008112495A1 (en) * | 2007-03-09 | 2008-09-18 | Wyeth | Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile |
| EP2139533A2 (en) * | 2007-04-27 | 2010-01-06 | Endo Pharmaceuticals Solutions Inc. | Implant device release agents and methods of using same |
| DK2868315T3 (en) | 2007-12-04 | 2017-09-04 | Biogen Chesapeake Llc | IMPROVED FORMULATIONS AND PROCEDURES FOR FREEZING DRYING AND THEREOF, LYOFILATES PREPARED |
| US8728528B2 (en) | 2007-12-20 | 2014-05-20 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| CN102014877B (zh) | 2008-01-25 | 2017-06-06 | 格吕伦塔尔有限公司 | 药物剂型 |
| PL2273983T3 (pl) * | 2008-05-09 | 2017-01-31 | Grünenthal GmbH | Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego |
| WO2009143404A1 (en) * | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
| CN104491962B (zh) | 2008-06-13 | 2018-10-23 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| ES2904623T3 (es) | 2008-06-20 | 2022-04-05 | Mannkind Corp | Aparato interactivo para establecer un perfil en tiempo real de esfuerzos de inhalación |
| BRPI0914336A2 (pt) * | 2008-06-25 | 2017-05-30 | Endo Pharmaceuticals Solutions | implante de octreotida com um agente de liberação |
| US8071537B2 (en) * | 2008-06-25 | 2011-12-06 | Endo Pharmaceuticals Solutions Inc. | Implantable device for the sustained release of a polypeptide |
| TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| CN102281870B (zh) | 2008-12-10 | 2015-03-04 | 安徽中人科技有限责任公司 | 新型控释组合物 |
| US8491880B2 (en) * | 2008-12-10 | 2013-07-23 | Mersana Therapeutics, Inc. | Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| CA2749993C (en) * | 2009-01-23 | 2016-12-20 | Surmodics Pharmaceuticals, Inc. | Continuous double emulsion process for making microparticles |
| MX2011009512A (es) | 2009-03-11 | 2011-11-29 | Mannkind Corp | Aparato, sistema y metodo para medir la resistencia de un inhalador. |
| US8734845B2 (en) | 2009-06-12 | 2014-05-27 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| US8877746B2 (en) * | 2009-08-25 | 2014-11-04 | Cardioklne, Inc | Compositions for delivery of insoluble agents |
| CA2775077C (en) * | 2009-09-22 | 2018-05-01 | Evonik Degussa Corporation | Implant devices having varying bioactive agent loading configurations |
| US9016147B2 (en) | 2009-11-03 | 2015-04-28 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
| WO2011095314A2 (en) * | 2010-02-03 | 2011-08-11 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
| EP2582421A1 (en) | 2010-06-21 | 2013-04-24 | MannKind Corporation | Dry powder drug delivery system and methods |
| EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
| NZ608865A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising an anionic polymer |
| CN103348000B (zh) * | 2011-02-07 | 2017-09-22 | 生命技术公司 | 用于稳定敏感化合物的组合物和方法 |
| US8925726B2 (en) | 2011-04-01 | 2015-01-06 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
| WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| JP2014521743A (ja) * | 2011-08-15 | 2014-08-28 | モアハウス スクール オブ メディスン | ガン細胞を特異的に標的とするための送達システムおよびその使用方法 |
| EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
| EP2790667B1 (en) | 2011-12-16 | 2017-03-22 | DSM IP Assets B.V. | Process for the manufacturing of a drug delivery system based on a polymer comprising a dispersed bioactive agent |
| BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| BR112015000529B1 (pt) | 2012-07-12 | 2022-01-11 | Mannkind Corporation | Inalador de pó seco |
| WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
| CA2906817C (en) | 2013-03-15 | 2022-01-18 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| EP3003283A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| EP3021834A1 (en) | 2013-07-18 | 2016-05-25 | MannKind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| CN105517607A (zh) | 2013-08-05 | 2016-04-20 | 曼金德公司 | 吹入设备和方法 |
| WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
| WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| EP3370694A1 (en) | 2015-11-06 | 2018-09-12 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293539A (en) * | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
| IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4818542A (en) * | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| CH665558A5 (en) | 1985-10-09 | 1988-05-31 | Debiopharm Sa | Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage |
| JPS62223112A (ja) | 1986-03-25 | 1987-10-01 | Rooto Seiyaku Kk | 歯周病治療剤 |
| IE59720B1 (en) | 1986-08-11 | 1994-03-23 | Innovata Biomed Ltd | Pharmaceutical formulations comprising microcapsules |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| AU2902289A (en) | 1987-12-08 | 1989-07-05 | Mark Chasin | Method of forming bioerodible implants for improved controlled drug release |
| FR2634376B1 (fr) * | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5439688A (en) * | 1989-07-28 | 1995-08-08 | Debio Recherche Pharmaceutique S.A. | Process for preparing a pharmaceutical composition |
| US5478564A (en) * | 1990-02-22 | 1995-12-26 | Teva Pharmaceutical Industries, Ltd. | Preparation of microparticles for controlled release of water-soluble substances |
| JPH05194253A (ja) | 1992-01-16 | 1993-08-03 | Kirin Brewery Co Ltd | 水溶性ポリペプチドホルモンを含む徐放性微小粒子状製剤及びその製造法 |
| DE4201179A1 (de) * | 1992-01-17 | 1993-07-22 | Alfatec Pharma Gmbh | Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung |
| DE69311538D1 (de) * | 1992-03-12 | 1997-07-17 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
| US5674534A (en) * | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5723508A (en) * | 1996-01-25 | 1998-03-03 | Northwestern University | Method of fabricating emulsion freeze-dried scaffold bodies and resulting products |
-
1996
- 1996-05-14 US US08/649,128 patent/US5817343A/en not_active Expired - Lifetime
-
1997
- 1997-01-07 US US08/779,777 patent/US6183781B1/en not_active Expired - Lifetime
- 1997-05-01 DK DK97921491T patent/DK0914095T3/da active
- 1997-05-01 AU AU27517/97A patent/AU718866B2/en not_active Ceased
- 1997-05-01 WO PCT/US1997/007441 patent/WO1997042940A1/en not_active Ceased
- 1997-05-01 ES ES97921491T patent/ES2180982T3/es not_active Expired - Lifetime
- 1997-05-01 AT AT97921491T patent/ATE221373T1/de not_active IP Right Cessation
- 1997-05-01 DE DE69714448T patent/DE69714448T2/de not_active Expired - Fee Related
- 1997-05-01 PT PT97921491T patent/PT914095E/pt unknown
- 1997-05-01 EP EP97921491A patent/EP0914095B1/en not_active Expired - Lifetime
- 1997-05-01 JP JP09540906A patent/JP2000513333A/ja not_active Ceased
- 1997-05-01 CA CA002253667A patent/CA2253667A1/en not_active Abandoned
-
2002
- 2002-03-25 US US10/106,862 patent/US20030031701A1/en not_active Abandoned
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
| US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
| US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
| US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| JP2009545564A (ja) * | 2006-08-02 | 2009-12-24 | メディオラヌム ファルマチェウティカルズ リミテッド | 長時間にわたって活性本体を放出する皮下移植物 |
| US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| JP2017500297A (ja) * | 2013-11-26 | 2017-01-05 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69714448T2 (de) | 2002-11-14 |
| AU2751797A (en) | 1997-12-05 |
| ATE221373T1 (de) | 2002-08-15 |
| DK0914095T3 (da) | 2002-11-11 |
| CA2253667A1 (en) | 1997-11-20 |
| US6183781B1 (en) | 2001-02-06 |
| ES2180982T3 (es) | 2003-02-16 |
| PT914095E (pt) | 2002-11-29 |
| US20030031701A1 (en) | 2003-02-13 |
| US5817343A (en) | 1998-10-06 |
| WO1997042940A1 (en) | 1997-11-20 |
| EP0914095B1 (en) | 2002-07-31 |
| DE69714448D1 (de) | 2002-09-05 |
| EP0914095A1 (en) | 1999-05-12 |
| AU718866B2 (en) | 2000-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000513333A (ja) | ポリマーを基剤とした制御された放出デバイスの製造方法 | |
| AU761472B2 (en) | Method of producing sub-micron particles of biologically active agents | |
| US6455074B1 (en) | Methods for fabricating polymer-based controlled release devices | |
| US5916597A (en) | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent | |
| AU772910B2 (en) | Method of producing submicron particles of a labile agent | |
| US7658998B2 (en) | Method of preparing sustained release microparticles | |
| US20040043077A1 (en) | Production of microspheres | |
| WO2005072702A2 (en) | Method for milling frozen microparticles | |
| JP2002524411A (ja) | 微粒子 | |
| KR100486028B1 (ko) | 단백질 함유 서방성 리피드 임플란트 및 이의 제조방법 | |
| KR100908517B1 (ko) | 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법 | |
| WO2001058428A1 (en) | Method of preparing a sustained release composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040428 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080129 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080701 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081028 |